Cover Image

Synergistic effects of methyl 2-cyano-3,11-dioxo-18beta-olean-1,-12-dien-30-oate and erlotinib on erlotinib-resistant non-small cell lung cancer cells

Non-small cell lung cancer (NSCLC) is often characterized by an underlying mutation in the epidermal growth factor receptor (EGFR), contributing to aggressive metastatic disease. Methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate (CDODA-Me), a glycyrrhetinic acid derivative, reportedly improve...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ebony Nottingham (Author), Elizabeth Mazzio (Author), Sunil Kumar Surapaneni (Author), Shallu Kutlehria (Author), Arindam Mondal (Author), Ramesh Badisa (Author), Stephen Safe (Author), Arun K. Rishi (Author), Mandip Singh (Author)
Format:	Book
Published:	Elsevier, 2021-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Modified Synthesis of Erlotinib Hydrochloride
by: Leila Barghi, et al.
Published: (2012)

Cutaneous leukocytoclastic vasculitis associated with erlotinib
by: Takahiro Sawada, et al.
Published: (2016)

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives
by: Long-fei Mao, et al.
Published: (2022)

Treatment of TRPV3 mutation-associated Olmsted syndrome with erlotinib
by: Kathleen E. Spitz, MD, MBA, et al.
Published: (2022)

Acute paronychia and reactive capillary proliferation in a patient on erlotinib
by: Ishmeet Kaur, et al.
Published: (2020)

Erlotinib resistance in Lung Cancer: Current Progress and Future Perspectives
by: Joy eTang, et al.
Published: (2013)

Development and Application of an HPLC Method for Erlotinib Protein Binding Studies
by: Soheila Bolandnazar, et al.
Published: (2013)

Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors
by: Xi-xi Hou, et al.
Published: (2022)

Synthesis and Antitumor Activity of Erlotinib Derivatives Linked With 1,2,3-Triazole
by: Peng Deng, et al.
Published: (2022)

The influence of ABCG2 polymorphism on erlotinib efflux in the K562 cell line
by: Anna Svedberg, et al.
Published: (2020)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015)

A rapid and convenient method for synthesis of anilinoquinazoline: an improved synthesis of erlotinib derivatives
by: Zahra Haghighijoo, et al.
Published: (2015)

HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment
by: Shen Y, et al.
Published: (2018)

Luteolin enhances erlotinib's cell proliferation inhibitory and apoptotic effects in glioblastoma cell lines
by: Erika Powe, et al.
Published: (2022)

Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation
by: Zhou X, et al.
Published: (2017)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
by: Al-Keilani MS, et al.
Published: (2018)

Quantitative determination of erlotinib in human serum using competitive enzyme-linked immunosorbent assay
by: Yuta Yamamoto, et al.
Published: (2018)

Aspartames Alter Pharmacokinetics Parameters of Erlotinib and Gefitinib and Elevate Liver Enzymes in Wistar Rats
by: Hajer AlRasheed, et al.
Published: (2022)

Severe cicatricial alopecia as a rare cutaneous side effect due to erlotinib - case report
by: Magdalena Żychowska, et al.
Published: (2016)

Synergistic Effects of 2-Deoxy-D-Glucose and Cinnamic Acid with Erlotinib on NSCLC Cell Line
by: Wrood salim Al-khfajy, et al.
Published: (2023)

Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1
by: Xuewei Cheng, et al.
Published: (2017)

Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction]
by: Zhou X, et al.
Published: (2022)

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
by: Togashi Y, et al.
Published: (2014)

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
by: Cong Wang, et al.
Published: (2018)

Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy
by: Sui H, et al.
Published: (2015)

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment
by: Shihui Bao, et al.
Published: (2021)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
by: Walleser S, et al.
Published: (2012)

Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
by: Wang Y, et al.
Published: (2016)

Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib
by: Yin N, et al.
Published: (2020)

Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib
by: Anyue Yin, et al.
Published: (2024)

Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies
by: Khalid Alhazzani, et al.
Published: (2023)

Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma
by: Zhuang H, et al.
Published: (2013)

Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo
by: Tan S, et al.
Published: (2017)

A Drug–Drug Interaction Study to Evaluate the Impact of Simvastatin and Itraconazole on Erlotinib Pharmacokinetics in Rats by UPLC-MS/MS
by: Fan Z, et al.
Published: (2023)

Scalable Production and In Vitro Efficacy of Inhaled Erlotinib Nanoemulsion for Enhanced Efficacy in Non-Small Cell Lung Cancer (NSCLC)
by: Gautam Chauhan, et al.
Published: (2023)

pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer
by: Xu Wan, et al.
Published: (2019)

Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions
by: Caixia Deng, et al.
Published: (2018)

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
by: Isla D, et al.
Published: (2016)

Case report: successful response to bevacizumab combined with erlotinib for a novel FH gene mutation hereditary leiomyoma and renal cell carcinoma
by: Xiaoming Bai, et al.
Published: (2024)